Newsfeeds - Spark Newswire

2 minute read

Sage Therapeutics And Biogen Initiate Rolling Submission Of New Drug Application To U.S. FDA For Zuranolone For The Potential Treatment Of Major Depressive Disorder

Today, 3:17 PM

Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major

BIIB

2 minute read

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight

By Shanthi Rexaline

Today, 3:17 PM

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that moved stocks during the week.

ACAD

2 minute read

Sage Therapeutics Highlights Presentation Of Results From Phase 2 LUMINARY Study Of SAGE-718 In Patients With Mild Cognitive Impairment And Mild Dementia Due To Alzheimer’s Disease

By Bill Haddad

Today, 3:17 PM

Data to be Presented During the Emerging Science Session at the American Academy of Neurology's 74th Annual Meeting The LUMINARY Study is a Phase 2, open-label study evaluating the safety, tolerability and efficacy

SAGE

1 minute read

Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Lowers Price Target to $57

By Benzinga Newsdesk

Today, 3:17 PM

Morgan Stanley maintains Sage Therapeutics (NASDAQ:SAGE) with a Equal-Weight and lowers the price target from $61 to $57.

SAGE

1 minute read

Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $40

By Benzinga Newsdesk

Today, 3:17 PM

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and lowers the price target from $60 to $40.

SAGE

2 minute read

Analyst Ratings

Expert Ratings For Sage Therapeutics

By Benzinga Insights

Today, 3:17 PM

Over the past 3 months, 4 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

SAGE

4 minute read

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

By Shanthi Rexaline

Today, 3:17 PM

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL